<DOC>
	<DOC>NCT00770302</DOC>
	<brief_summary>Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This Phase I study is designed to assess the pharmacokinetics of saxagliptin and its pharmacologically active metabolite, BMS-510849, following single and multiple oral doses of 5 mg saxagliptin in healthy Chinese subjects.</brief_summary>
	<brief_title>Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin</brief_title>
	<detailed_description />
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Men or women (not of childbearing potential) of Chinese ethnicity Weigh at least 50 kg and have a body mass index (BMI) between 19 and 24 kg/m2 Must have normal physical examination, laboratory values, ECG, pulse and blood pressure unless the investigator considers an abnormality to not be clinically significant. History of clinically significant hypoglycaemia (low blood sugar levels) Women who are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>DPP-4 inhibitors</keyword>
	<keyword>HBA1c</keyword>
	<keyword>Incretins</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>